BCG vaccine immunity against human tuberculosis. The BCG vaccine can be anywhere from 0 to 80% effective in preventing tuberculosis for a duration of 15 years; however, its protective effect appears to vary according to geography and the lab in which the vaccine strain was grown. A number of different companies make BCG, sometimes using different genetic strains of the bacterium. This may result in different product characteristics. OncoTICE, used for bladder instillation for bladder cancer, was developed by Organon Laboratories (since acquired by Schering-Plough, and in turn acquired by Merck & Co.). Pacis BCG, made from the Montréal (Institut Armand-Frappier) strain,
Inoculation theory restore original beliefs and attitudes after the counterarguments have been made. Results of the research reinforced prior conclusions that refutational same and different treatments both increase resistance to attacks. More important, results also indicated inoculation was superior to post hoc refutation when attempting to protect original beliefs and attitudes (Pfau et al., 1990). Much of the research conducted in health is attempting to create campaigns that will encourage people to stop unhealthy behaviors (e.g. getting people to stop smoking or prevention of teen alcoholism). Compton, Jackson and Dimmock (2016) reviewed studies where inoculation theory was applied to health-related messaging. There